Cardiovascular effect of a new 1,5-benzothiazepine derivative TA-993 in anesthetized dogs

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 2, 1998, Pages 240-247

  Kaburaki, Minako ^a   Narita, Hiroshi ^a   Yabana, Hideo ^a   Karasawa, Tadashi ^a   Doi, Hisayoshi ^a   Murata, Sakae ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

1,5 Benzothiazepine derivative; Cardiovascular effect; Dogs; TA 993

Indexed keywords

3 ACETOXY 5 [2 (DIMETHYLAMINO)ETHYL] 2,3 DIHYDRO 8 METHYL 2 (4 METHYLPHENYL) 1,5 BENZOTHIAZEPIN 4(5H) ONE MALEATE; BENZOTHIAZEPINE DERIVATIVE; DILTIAZEM; HEXAMETHONIUM; POTASSIUM ION; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERY BLOOD FLOW; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BRACHIAL ARTERY; CARDIOVASCULAR EFFECT; CAROTID ARTERY FLOW; COMMON CAROTID ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG POTENCY; FEMALE; FEMORAL ARTERY; FEMORAL ARTERY FLOW; HEART OUTPUT; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION;

ANIMALS; BRACHIAL ARTERY; CARDIOVASCULAR AGENTS; CAROTID ARTERIES; DILTIAZEM; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; FEMORAL ARTERY; GANGLIONIC BLOCKERS; HEMODYNAMIC PROCESSES; HEXAMETHONIUM; INJECTIONS, INTRAVENOUS; MALE; REGIONAL BLOOD FLOW; TIME FACTORS; VASODILATION;

EID: 0031886174     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199802000-00009     Document Type: Article

References (23)

1. Odawara A, Kikkawa K, Katoh M, Toryu H, Shimazaki T, Sasaki Y. Inhibitory effects of TA-993, a new 1,5-benzothiazepine derivative, on platelet aggregation. Circ Res 1996;78:643-9.
2. Kaburaki M, Doi H, Narita H, Odawara A, Yasoshima A, Murata S. Antithrombotic action of TA-993, a new 1, 5-benzothiazepine derivative, in a canine model of femoral arterial thrombosis. J Cardiovasc Pharmacol 1998 (in press).
3. Narita H, Kaburaki M, Doi H, Yasoshima A, Murata S. Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats. Jpn J Pharmacol 1995;68:397-404.
4. Klein W, Brandt D, Vrecko K, Härringer M. Role of calcium antagonists in the treatment of essential hypertension. Circ Res 1983;52(suppl I):174-81.
5. Rosenthal SJ, Lamb IH, Schroeder JS, Ginsburg R. Long-term efficacy of diltiazem for control of symptoms of coronary artery spasm. Circ Res 1983;52(suppl I):153-7.
6. Safar ME, Simon AC, Levenson JA, Cazor JL. Hemodynamic effects of diltiazem in hypertension. Circ Res 1983;52(suppl I):169-73.
7. Yasue H, Omote S, Takizawa A, Nagao M. Coronary arterial spasm in ischemic heart disease and its pathogenesis: a review. Circ Res 1983;52(suppl I):147-52.
8. Sato M, Nagao T, Yamaguchi I, Nakajima H, Kiyomoto A. Pharmacological studies on a new 1,5-benzothiazepine derivative (CRD-401): cardiovascular actions. Arzneimittelforschung/Drug Res 1971;21:1338-43.
9. Nagao T, Ikeo T, Sato M. Influence of calcium ions on responses to diltiazem in coronary arteries. Jpn J Pharmacol 1977;27:330-2.
10. Ito Y, Kuriyama H, Suzuki H. The effects of diltiazem (CRD-401) on the membrane and mechanical properties of vascular smooth muscles of the rabbit. Br J Pharmacol 1978;64:503-10.
11. Fujiwara S, Ito Y, Itoh T, Kuriyama H, Suzuki H. Diltiazem-induced vasodilation of smooth muscle cells of the canine basilar artery. Br J Pharmacol 1982;75:455-67.
12. Nagao T, Sato M, Nakajima H. Studies on a new 1,5-benzothiazepine derivative (CRD-401 ). II. Vasodilator actions. Jpn J Pharmacol 1972;22:1-10.
13. Nagao T, Sato M, Nakajima H, Kiyomoto A. Studies on a new 1,5-benzothiazepine derivative (CRD-401). IV. Coronary vasodilating effect and structure-activity relationship. Chem Pharm Bull (Tokyo) 1973;21:92-7.
14. Tanaka T, Inoue H, Date T, et al. Synthesis of the optically active trans-isomers of diltiazem and their cardiovascular effects and Caantagonistic activity. Chem Pharm Bull (Tokyo) 1992;40:1476-80.
15. Kikkawa K, Murata S, Nagao T. Calcium antagonistic and spas-molytic activities of a new 1,5-benzothiazepine derivative in isolated canine and monkey arteries. Arzneimittelforschung/Drug Res 1988;38(I):526-31.
16. Murata S, Kikkawa K, Yabana H, Nagao T. Cardiovascular effects of a new 1,5-benzothiazepine calcium antagonist in anesthetized dogs. Arzneimittelforschung/Drug Res 1988;38(I):521-5.
17. Inoue H, Konda M, Hashiyama T, et al. Synthesis of halogen-substituted 1,5-benzothiazepine derivatives and their vasodilating and hypotensive activities. J Med Chem 1991;34:675-87.
18. Nasa Y, Ichihara K, Abiko Y. Both d-cis and l-cis-diltiazem have antiischemic action in the isolated, perfused working rat heart. J Pharmacol Exp Ther 1990;255:680-9.
19. Stem JH, Kaupp UB, MacLeish PR. Control of the light-regulated current in rod photoreceptors by cyclic GMP, calcium, and l-cis-diltiazem. Proc Natl Acad Sci U S A 1986;83:1163-7.
20. Kiyomoto A, Sasaki Y, Odawara A, Morita T. Inhibition of platelet aggregation by diltiazem: comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites. Circ Res 1983;52(suppl I):115-9.
21. Corner PI. Central nervous control of autonomic cardiovascular function. In: Geiger SR, ed. Handbook of physiology: the cardiovascular system 1. Bethesda, MD: American Physiological Society, 1979:691-739.
22. Smith OA. Reflex and central mechanisms involved in the control of the heart and circulation. Anna Rev Physiol 1974;36:93-123.
23. Donald DE. Splanchnic circulation. In: Geiger SR, ed. Handbook of physiology: the cardiovascular system 3. Bethesda, MD: American Physiological Society, 1983:219-40.